New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
10:00 EDTKING, RNG, IRT, CIG, ASBC, COMM, TCB, REGN, ICLR, CELG, AMGN, USPH, RNDY, PCYC, GILD, BIIB, ACPWOn The Fly: Analyst Initiation Summary
Active Power (ACPW) initiated with a Buy at Roth Capital... Amgen (AMGN) initiated with an Overweight at Morgan Stanley... Associated Banc-Corp (ASBC) initiated with a Neutral at DA Davidson... Biogen (BIIB) initiated with an Overweight at Morgan Stanley... Celgene (CELG) initiated with an Equal Weight at Morgan Stanley... Cemig (CIG) initiated with a Buy at Goldman... Gilead (GILD) initiated with an Equal Weight at Morgan Stanley... ICON plc (ICLR) initiated with an Outperform at Credit Suisse... Independence Realty Trust (IRT) initiated with a Buy at Deutsche Bank... Pharmacyclics (PCYC) initiated with an Equal Weight at Morgan Stanley... Regeneron (REGN) initiated with an Equal Weight at Morgan Stanley... RingCentral (RNG) initiated with an Outperform at Macquarie... Roundy's (RNDY) initiated with a Buy at BofA/Merrill... TCF Financial (TCB) initiated with a Neutral at DA Davidson... King Digital (KING) initiated with a Neutral at Sterne Ageel... U.S. Physical Therapy (USPH) initiated with an Overweight at Stephensl... CommScope (COMM) initiated with a Buy at Longbow.
News For ACPW;AMGN;ASBC;BIIB;CELG;CIG;GILD;ICLR;IRT;PCYC;REGN;RNG;RNDY;TCB;KING;USPH;COMM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
June 30, 2015
07:03 EDTCELGJuno volatility low into announcing immunotherapy collaboration with Celgene
Subscribe for More Information
June 29, 2015
19:01 EDTCELGOn The Fly: After Hours Movers
HIGHER: Juno Therapeutics (JUNO), up 38.4% after announcing immunotherapy collaboration with Celgene (CELG)... Kite Pharma (KITE) and Lion Biotechnologies (LBIO) are up 8.7% and 5.7% respectively, following Juno's collaboration with Celgene. DOWN AFTER EARNINGS: CHC Group (HELI), down 8%... Apollo Education (APOL), down 6.2%. ALSO LOWER: EnteroMedics (ETRM), down 12.4% after filing to sell common stock and warrants... Celgene (CELG), down 1% after Juno announces immunotherapy collaboration.
18:09 EDTCELGJuno surges after Celgene collaboration, CAR-T peers follow
Subscribe for More Information
16:30 EDTGILDFDA sued by advocacy groups for Gilead Hep-C drug trial data, Reuters says
Subscribe for More Information
16:09 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Celgene (CELG) and Juno Therapeutics (JUNO) announced a global collaboration for the development and commercialization of immunotherapies. The two companies will leverage T cell therapeutic strategies to develop treatments for patients with cancer and autoimmune diseases with an initial focus on Chimeric Antigen Receptor Technology and T Cell Receptor technologies. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. Under the terms of the collaboration, Celgene has the option to be the commercialization partner for Juno’s oncology and cell therapy auto-immune product candidates, including Juno’s CD19 and CD22 directed CAR-T product candidates. B-Cell Maturation Antigen is excluded as a target in this collaboration. For Juno-originated programs co-developed under the collaboration: Juno will be responsible for research and development in North America and will retain commercialization rights in those territories; Celgene will be responsible for development and commercialization in the rest of the world, and will pay Juno a royalty on sales in those territories; and Celgene has certain co-promotion options: Celgene will initially be eligible to select two programs, excluding CD19 and CD22, to be subject to a global profit sharing agreement under which the companies will share worldwide expenses and profits equally, except in China; and Additionally, subject to additional obligations, Celgene may select a third program. Juno will have the option to enter into a co-development and co-commercialization agreement on certain Celgene-originated development candidates that target T Cells. For any such Celgene-originated programs co-developed under the collaboration: The parties will share global costs and profits with 70% allocated to Celgene and 30% allocated to Juno; and Celgene will lead global development and commercialization, subject to a Juno co-promote option in the US and certain EU territories. Upon closing, Juno will receive an upfront payment of approximately $150M, and in addition Celgene will purchase 9,137,672 shares of Juno’s common stock at $93.00 per share. In conjunction with this stock purchase: Celgene will receive the right to nominate a member to Juno’s board of directors; During the 10-year term of the collaboration, Celgene will have the right to purchase additional equity in Juno during specified windows and at specified market premiums subject to satisfaction of certain conditions by each party including Juno opting in on select Celgene programs, such that, at a maximum, Celgene could own up to 30% of Juno’s common stock then outstanding; and Celgene has entered into a standstill agreement and agreed to certain lock-up provisions on its share ownership. This transaction has been approved by the boards of directors of both companies. Celgene and Juno currently expect to complete the transaction during the third quarter of 2015, subject to the expiration or termination of applicable waiting periods under all applicable antitrust laws and satisfaction of other usual and customary closing conditions.
16:08 EDTCELGJuno jumps 45% after announcing immunotherapy collaboration with Celgene
Subscribe for More Information
16:07 EDTCELGCelgene, Juno Therapeutics announce ten year collaboration
Subscribe for More Information
June 26, 2015
11:32 EDTCELGCelgene looks to protect itself from Kyle Bass patent challenges, WSJ says
Subscribe for More Information
09:48 EDTCIGCemig upgraded to Neutral from Underweight at JPMorgan
05:25 EDTREGNRegeneron reports approval of Eylea by Japan
Subscribe for More Information
05:21 EDTBIIBBiogen, Sobi announce EMA validates MAA for Alprolix
Biogen and Swedish Orphan Biovitrum AB, or Sobi, announced that the European Medicines Agency, or EMA, has accepted the Marketing Authorization Application, or MAA, of Alprolix, a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process. The MAA includes results from two global, Phase 3 clinical trials examining the efficacy, safety and pharmacokinetics of ALPROLIX for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12.
June 25, 2015
12:59 EDTBIIBOptions with increasing implied volatility
Subscribe for More Information
09:34 EDTGILDActive equity options trading on open
Active equity options trading on open: AAPL FB NFLX AMZN BAC CVX TWTR INTC GILD BBBY
June 24, 2015
11:16 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility: WMB AMZN CMG BIIB VMW QLIK ISRG FB UA FFIV
07:56 EDTAMGNAmgen management to meet with Evercore ISI
Subscribe for More Information
June 23, 2015
14:10 EDTGILDGilead price target raised to $150 from $130 at Argus
Subscribe for More Information
11:00 EDTBIIBOptions with increasing implied volatility
Options with increasing implied volatility:TRIP WPZ CMG BIIB WMB AMZN ISRG VMW
07:55 EDTBIIBBiogen's Tysabri in SPMS a $1B-$2B opportunity, says Morgan Stanley
Subscribe for More Information
07:25 EDTAMGNPiper Jaffray to hold a summit
2015 Piper Jaffray Heartland Summit is being held in Minneapolis on June 23-24.
June 22, 2015
09:40 EDTGILDActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use